ÂÜÀòÂÒÂ×

Mr. Moulder, Founder of Zenas BioPharma, serves as our Executive Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a fully-integrated Boston based oncology-focused biopharmaceutical company) and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.